Lung Cancer Europe will hold an event on 28th November at the EU Parliament to highlight the current challenges in clinical trials across Europe Within the…
According to Globocan 2018, in both sexes combined, lung cancer is the most commonly diagnosed cancer (11.6% of the total cases) and the leading cause…
LuCE president, Stefania Vallone provided an insight analysis on “Being heard over the noise: The patient viewpoint” during #ESMO2018. She emphasized the role can patients…
We invite all interested ESMO members to visit us @LuCE booth located in the society village at ESMO 2018 in Munich. Name: LuCEHall: B1Stand: PA 8 LuCE…
According to tthe new statistics, in both sexes combined, lung cancer is the most commonly diagnosed cancer (11.6 % of the total cases) and the…
During the congress, one of the topics covered focused on the importance of EGFR TKIs in Advanced NSCLC. Apply expert recommendations for frontline therapy for…
During the World Congress on Lung Cancer held this year in Toronto, Canada were presented the findings of NELSON study. These demonstrate that the use…
Starting September, Alfonso Aguarón (second from left) is LuCE’s new project manager. He has extensive experience in patient advocacy field as Hodgkin’s Lymphoma survivor. This…
A new scale for tumour DNA mutations which will simplify and standardise choices for targeted cancer treatment has been agreed by leading cancer specialists in Europe…